FealtySign in
Promise-keeping streak4 kept in a rowguidance & buyback

Abbott Laboratories

(ABT)

CIK 1800 · SEC filings only

Not gradedDividend record
shown as history
company entity
42 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

42 declarations · 13 raised · 25 held · 0 cut · held 7 quarters

  1. RAISED$0.6300/shperiod ended 2026-03-31Filing ↗
  2. HELD$0.5900/shperiod ended 2025-09-30Filing ↗
  3. HELD$0.5900/shperiod ended 2025-06-30Filing ↗
  4. RAISED$0.5900/shperiod ended 2025-03-31Filing ↗
  5. HELD$0.5500/shperiod ended 2024-09-30Filing ↗
  6. HELD$0.5500/shperiod ended 2024-06-30Filing ↗
  7. RAISED$0.5500/shperiod ended 2024-03-31Filing ↗
  8. INITIATED$0.5100/shperiod ended 2023-09-30Filing ↗
  9. INITIATED$0.3600/shperiod ended 2020-03-31Filing ↗
  10. RAISED$0.3200/shperiod ended 2019-03-31Filing ↗
  11. HELD$0.2800/shperiod ended 2018-09-30Filing ↗
  12. HELD$0.2800/shperiod ended 2018-06-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
2 resolved promises

Not enough resolved promises to grade

2 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Credibility timeline

KEPT · Nov 5, 2015KEPT · Feb 17, 2017
20152017
Timeline as a list
  • Nov 5, 2015KEPTThe board of directors also authorized the repurchase of up to $3 billion of Abbott’s common shares
  • Feb 17, 2017KEPTthe board of directors of Abbott authorized the repurchase of up to $3 billion of Abbott’s common shares
2 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
BGuidance record
grade
company entity
19 resolved promises

Sector median (Life Sciences): B across 7 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

20 of 39 guidance figures that were graded or dropped for basis could not be graded on the same basis (51%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · basis not stated3003
EPS · GAAP3519016
EPS · non-GAAPcannot be graded3501916
EPS · basis not statedcannot be graded1010

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (39)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Jul 20, 2022
    Abbott is raising its projected adjusted diluted earnings per share to at least $4.90 for the full-year 2022
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 20, 2022
    projected adjusted diluted earnings per share of at least $4.70 remains unchanged for the full-year 2022
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Jan 26, 2022
    full-year adjusted diluted EPS from continuing operations of at least $4.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance q · Jan 26, 2022
    projected adjusted diluted earnings per share from continuing operations would be at least $1.50 for the first quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Oct 20, 2021
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $5.00 to $5.10 for full-year 2021
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Jul 22, 2021
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for full-year 2021
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Jan 27, 2021
    full-year adjusted diluted EPS from continuing operations of at least $5.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 21, 2020
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.55 for full-year 2020
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Jul 16, 2020
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.25 for full-year 2020
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. revenue guidance fy · Jan 22, 2020
    Abbott is issuing full-year 2020 guidance for organic sales growth of 7.0 to 8.0 percent
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  11. eps guidance q · Jan 22, 2020
    projected adjusted diluted earnings per share from continuing operations would be $0.69 to $0.71 for the first quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Jan 22, 2020
    projected adjusted diluted earnings per share from continuing operations would be $3.55 to $3.65 for the full year 2020
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. revenue guidance fy · Jul 17, 2019
    Abbott projects organic sales growth of 7.0 to 8.0 percent
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  14. eps guidance q · Jul 17, 2019
    projected adjusted diluted earnings per share from continuing operations would be $0.83 to $0.85 for the third quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Jul 17, 2019
    projected adjusted diluted earnings per share from continuing operations would be $3.21 to $3.27 for the full year 2019
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. revenue guidance fy · Jan 23, 2019
    Abbott is issuing full-year 2019 guidance for organic sales growth of 6.5 to 7.5 percent
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  17. eps guidance fy · Jan 23, 2019
    projected adjusted diluted earnings per share from continuing operations would be $3.15 to $3.25 for the full year 2019
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance q · Jan 23, 2019
    projected adjusted diluted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Oct 17, 2018
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $2.87 to $2.89 for the full year 2018.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance q · Oct 17, 2018
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.80 to $0.82 for the fourth quarter.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Jul 18, 2018
    Projected full-year adjusted diluted EPS from continuing operations is now $2.85 to $2.91.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance q · Jul 18, 2018
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.73 to $0.75 for the third quarter.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance q · Jan 24, 2018
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.57 to $0.59.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · Jan 24, 2018
    Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $2.80 to $2.90 for the full year 2018.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Jul 20, 2017
    Projected diluted earnings per share from continuing operations on an adjusted basis is now $2.43 to $2.53 for the full year 2017.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Apr 19, 2017
    Projected adjusted diluted earnings per share from continuing operations remains unchanged at $2.40 to $2.50 for the full year 2017
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · Jul 20, 2016
    Excluding specified items, projected earnings per share from continuing operations remains unchanged at $2.14 to $2.24 for the full year 2016.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance q · Jan 28, 2016
    Abbott is issuing first-quarter 2016 guidance for earnings per share, excluding specified items, of $0.38 to $0.40.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Jan 28, 2016
    Abbott is issuing full-year 2016 guidance for earnings per share, excluding specified items, of $2.10 to $2.20.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Jul 22, 2015
    Abbott’s full-year 2015 adjusted EPS guidance range for continuing operations remains unchanged at $2.10 to $2.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Jan 29, 2015
    Abbott issues full-year 2015 EPS guidance for continuing operations, excluding specified items, of $2.10 to $2.20.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance q · Jan 29, 2015
    Abbott is issuing first-quarter 2015 guidance for earnings-per-share guidance from continuing operations, excluding specified items, of $0.41 to $0.43.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Oct 22, 2014
    Abbott is raising the mid-point and narrowing its full-year 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance q · Oct 22, 2014
    Abbott is issuing fourth-quarter 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Apr 16, 2014
    Abbott is confirming its full-year 2014 ongoing EPS guidance of $2.16 to $2.26
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance fy · Oct 16, 2013
    Abbott is confirming its full-year 2013 ongoing earnings-per-share guidance range of $1.98 to $2.04
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Jul 17, 2013
    Abbott is confirming ongoing earnings-per-share guidance for the full year 2013 of $1.98 to $2.04.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · Oct 17, 2012
    Abbott is narrowing its ongoing earnings-per-share guidance for the full-year 2012 to $5.06 to $5.08
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · Apr 18, 2012
    Abbott is raising its ongoing earnings-per-share guidance for 2012 to $5.00 to $5.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (2) · 14 superseded

Open · eps guidance q

Including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34 for the fourth quarter

unresolved — no outcome on filereceipt (opens in a new tab)
Open · eps guidance q

Abbott is issuing fourth-quarter 2018 guidance for diluted earnings per share from continuing operations under GAAP of $0.39 to $0.41.

unresolved — no outcome on filereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott projects full-year 2020 diluted EPS from continuing operations on a GAAP basis of at least $2.00

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott continues to project earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $0.92 to $1.02

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott projects full-year 2022 diluted EPS on a GAAP basis of at least $3.35

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott projects full-year diluted EPS from continuing operations on a GAAP basis of $1.34 to $1.40.

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.39 to $1.45 for the full year 2013.

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $2.35 to $2.45

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Projected full-year 2014 EPS from continuing operations under GAAP is $1.13 to $1.23

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $1.80 to $1.90

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott issues full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.74

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Projected full-year 2016 EPS under GAAP is $1.55 to $1.65.

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Projected full-year 2015 EPS for continuing operations under GAAP is $1.33 to $1.43.

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Abbott is issuing full-year 2018 guidance for diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $1.22 to $1.32.

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

ABOVE · May 2, 2018IN LINE · Oct 31, 2018IN LINE · Feb 22, 2019ABOVE · May 1, 2019IN LINE · Oct 31, 2019IN LINE · Feb 21, 2020WITHDRAWN · Apr 16, 2020BELOW · Apr 29, 2020IN LINE · Feb 19, 2021ABOVE · Feb 18, 2022IN LINE · May 3, 2022IN LINE · Feb 17, 2023
20182023
Timeline as a list
  • May 2, 2018ABOVEAbbott is issuing first-quarter 2018 guidance for diluted earnings per share from continuing operations under GAAP of $0.16 to $0.18.
  • Oct 31, 2018IN LINEAbbott is issuing third-quarter 2018 guidance for diluted earnings per share from continuing operations under GAAP of $0.32 to $0.34.
  • Feb 22, 2019IN LINEAbbott is narrowing its 2018 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) to $1.33 to $1.35.
  • May 1, 2019ABOVEfirst-quarter 2019 guidance for diluted earnings per share from continuing operations under GAAP of $0.25 to $0.27
  • Oct 31, 2019IN LINEthird-quarter 2019 guidance for diluted earnings per share from continuing operations under GAAP of $0.53 to $0.55
  • Feb 21, 2020IN LINEdiluted EPS from continuing operations on a GAAP basis of $2.06 to $2.12
  • Apr 16, 2020WITHDRAWNAbbott is suspending its previously announced annual guidance for 2020.
  • Apr 29, 2020BELOWfirst-quarter 2020 guidance for diluted earnings per share from continuing operations under GAAP of $0.40 to $0.42
  • Feb 19, 2021IN LINEAbbott projects full-year 2020 diluted EPS from continuing operations on a GAAP basis of at least $2.35
  • Feb 18, 2022ABOVEAbbott projects 2021 diluted earnings per share from continuing operations under GAAP of $3.55 to $3.65
  • May 3, 2022IN LINEAbbott projects first-quarter 2022 diluted earnings per share from continuing operations under GAAP of at least $1.20
  • Feb 17, 2023IN LINEAbbott projects full-year diluted EPS on a GAAP basis of at least $3.50
19 resolved guidance promises · 39 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →